戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  the phase 3 development of grazoprevir plus elbasvir.
2 red treatment group received grazoprevir and elbasvir.
3 n, 8 or 12 weeks of treatment, and dosage of elbasvir.
4 oing phase 3 development of grazoprevir plus elbasvir.
5 eceive 12 weeks of grazoprevir (100 mg) plus elbasvir (20 mg or 50 mg) with or without ribavirin (arm
6 l, once-daily, fixed-dose grazoprevir 100 mg/elbasvir 50 mg for 12 weeks, stratified by fibrosis and
7 ll patients received grazoprevir 100 mg plus elbasvir 50 mg in a fixed-dose combination tablet once d
8 l trial of grazoprevir 100 mg once daily and elbasvir 50 mg once daily coadministered with weight-bas
9 e enrolled at 68 centres worldwide to either elbasvir 50 mg plus grazoprevir 100 mg once per day for
10 t group) or placebo for 12 weeks followed by elbasvir 50 mg plus grazoprevir 100 mg once per day for
11 ts to receive grazoprevir (100 mg daily) and elbasvir (50 mg daily) with or without ribavirin for 12
12 mg once daily) and an NS5A inhibitor, either elbasvir (50 mg once daily) or ruzasvir (MK-8408; 60 mg
13 o 8 or 12 weeks of grazoprevir (100 mg) plus elbasvir (50 mg) with or without ribavirin (arms B1-3) a
14 evir (100 mg, NS3/4A protease inhibitor) and elbasvir (50 mg, NS5A inhibitor; immediate treatment gro
15  (450 mg/day); grazoprevir (100 mg/day) plus elbasvir (50 mg/day) plus uprifosbuvir (300 mg/day); or
16 00 mg/day); or grazoprevir (100 mg/day) plus elbasvir (50 mg/day) plus uprifosbuvir (450 mg/day), acc
17                                  Grazoprevir-elbasvir achieved high SVR12 rates in treatment-naive ci
18 HCV NS3/4A protease inhibitor) combined with elbasvir (an HCV NS5A inhibitor) with or without ribavir
19                           BACKGROUND & AIMS: Elbasvir (an NS5A inhibitor) and grazoprevir (an NS3/4A
20                                              Elbasvir (an NS5A inhibitor) and grazoprevir (an NS3/4A
21 herapy with grazoprevir (in combination with elbasvir, an inhibitor of HCV NS5A protein) showed that
22          However, 12 weeks of treatment with elbasvir and grazoprevir failed in a small proportion of
23  with HCV genotype 1a infection who received elbasvir and grazoprevir for 12 weeks, baseline HCV gene
24 s (n = 6), an intensified 16-week regimen of elbasvir and grazoprevir plus ribavirin could increase e
25  NS5A polymorphisms, all 26 who received the elbasvir and grazoprevir regimens recommended in prescri
26 om selected phase 2 and 3 clinical trials of elbasvir and grazoprevir, with and without ribavirin.
27 lyses of drug resistance data from trials of elbasvir and grazoprevir, with and without ribavirin.
28                           The combination of elbasvir and grazoprevir, with or without ribavirin is s
29                                    Trials of elbasvir and grazoprevir, with or without ribavirin, dem
30 ration to support the regulatory approval of elbasvir and grazoprevir.
31 ly efficient synthesis of HCV drug candidate elbasvir, and has been applied to the synthesis of chira
32              Treatment with grazoprevir plus elbasvir, both with and without ribavirin and for both 1
33 ss sensitive to daclatasvir, ledipasvir, and elbasvir, but equally sensitive to ombitasvir, velpatasv
34                        All patients received elbasvir (EBR) 50 mg/grazoprevir (GZR) 100 mg with sofos
35 (HCV) guidelines do not recommend the use of elbasvir (EBR)/grazoprevir (GZR) in postliver transplant
36                   Once-daily grazoprevir and elbasvir for 12 weeks had a low rate of adverse events a
37  were enrolled and received grazoprevir plus elbasvir for 12 weeks, all of whom completed follow-up a
38 udy was to assess the safety and efficacy of elbasvir/grazoprevir (EBR/GZR) in patients with inherite
39 d tolerability of grazoprevir (MK-5172) plus elbasvir (MK-8742) in patients with HCV and HIV co-infec
40  NS3/4A protease inhibitor) and two doses of elbasvir (MK-8742; HCV NS5A inhibitor) in patients with
41 mediate treatment group with grazoprevir and elbasvir (n=111) or the deferred treatment group (n=113)
42 ce for the fixed-dose combination regimen of elbasvir plus grazoprevir for 12 weeks and support use o
43 he C-SURFER study, therapy with the all-oral elbasvir plus grazoprevir regimen for 12 weeks in patien
44  regimen (ten [71%] of 14), grazoprevir plus elbasvir plus uprifosbuvir 300 mg regimen (11 [69%] of 1
45 egimen (11 [69%] of 16), or grazoprevir plus elbasvir plus uprifosbuvir 450 mg regimen (nine [60%] of
46 ions of daclatasvir, ledipasvir, ombitasvir, elbasvir, ruzasvir, velpatasvir, and pibrentasvir in cul
47 f the 122 patients receiving grazoprevir and elbasvir, six were excluded from the primary efficacy an
48 inhibitor grazoprevir and the NS5A inhibitor elbasvir together with ribavirin in treatment-experience
49 on of a key intermediate in the synthesis of Elbasvir, which is a novel therapy for the treatment of
50                  Once-daily grazoprevir plus elbasvir with or without ribavirin for 12 weeks in previ
51 domised controlled trial of grazoprevir plus elbasvir with or without ribavirin in patients with HCV;
52       The safety profile of grazoprevir plus elbasvir with or without ribavirin was similar in mono-i
53 open-label phase 2 trial of grazoprevir plus elbasvir with or without ribavirin; here we report findi
54                              Grazoprevir and elbasvir with ribavirin for 12 weeks maintained HCV supp
55 s treated for 12 weeks with grazoprevir plus elbasvir without ribavirin, 97% (95% CI 82-100, 28/29) o

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。